Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer’s disease

Effect of TTP488 in patients with mild to moderate Alzheimer’s disease

(2014) Aaron H Burstein et al.   BMC Neurology

RAGE Inhibition in Microglia Prevents Ischemia-Dependent Synaptic Dysfunction in an Amyloid-Enriched Environment

(2014) N. Origlia et al.   JOURNAL OF NEUROSCIENCE

Clinical trial of an inhibitor of RAGE-A  interactions in Alzheimer disease

(2014) D. Galasko et al.   NEUROLOGY

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Amyloid-β and Tau

(2014) George S. Bloom   JAMA Neurology

The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy

(2013) Patrick L. McGeer et al.   ACTA NEUROPATHOLOGICA

Inflammatory components in human Alzheimer’s disease and after active amyloid-β42 immunization

(2013) Elina Zotova et al.   BRAIN

Alzheimer disease in the United States (2010-2050) estimated using the 2010 census

(2013) L. E. Hebert et al.   NEUROLOGY

Hypertension Induces Brain β-Amyloid Accumulation, Cognitive Impairment, and Memory Deterioration Through Activation of Receptor for Advanced Glycation End Products in Brain Vasculature

(2012) Daniela Carnevale et al.   HYPERTENSION

A multimodal RAGE-specific inhibitor reduces amyloid β–mediated brain disorder in a mouse model of Alzheimer disease

(2012) Rashid Deane et al.   JOURNAL OF CLINICAL INVESTIGATION

Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is ‘too big to fail’

(2011) Rudy J Castellani et al.   JOURNAL OF PATHOLOGY

PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease

(2010) Marwan N. Sabbagh et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Alzheimer's Disease

(2010) Henry W. Querfurth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer’s disease

(2009) Ling Zhang et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease

(2009) R. Deane et al.   CNS & Neurological Disorders-Drug Targets

RAGE-dependent signaling in microglia contributes to neuroinflammation, Aβ accumulation, and impaired learning/memory in a mouse model of Alzheimer’s disease

(2009) Fang Fang et al.   FASEB JOURNAL

The sour side of neurodegenerative disorders: the effects of protein glycation

(2009) Hugo Vicente Miranda et al.   JOURNAL OF PATHOLOGY

Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease

(2009) Velandai Srikanth et al.   NEUROBIOLOGY OF AGING

Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease

(2008) Miles C. Miller et al.   BRAIN RESEARCH

Evidence for Altered LRP/RAGE Expression in Alzheimer Lesion Pathogenesis

(2008) Brian Jeynes et al.   Current Alzheimer Research

The Role of the Cell Surface LRP and Soluble LRP in Blood-Brain Barrier Aβ Clearance in Alzheimers Disease

(2008) R. Deane et al.   CURRENT PHARMACEUTICAL DESIGN

Possible Involvement of Advanced Glycation End-Products (AGEs) in the Pathogenesis of Alzheimers Disease

(2008) Masayoshi Takeuchi et al.   CURRENT PHARMACEUTICAL DESIGN

Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment

(2008) R. Ghidoni et al.   JOURNAL OF NEURAL TRANSMISSION